leadf
logo-loader
viewCynata Therapeutics Ltd

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Snapshot

Dr Ross Macdonald talked stemcell research with investors.

Cynata-CEO-Dr-Ross-Macdonald-presenting-Syd-Mar-2017.jpg

Quick facts: Cynata Therapeutics Ltd

Price: 1.04 AUD

ASX:CYP
Market: ASX
Market Cap: $121.81 m
Follow

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.

Cynata is now in a transition to a clinical stage company, with the focus on stem cells and regenerative medicine.

Earlier this year Cynata announced a breakthrough strategic partnership with Fujifilm which included the Japanese company investing in the company to become the largest shareholder.

 

ACCESS THE FULL PRESENTATION HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Cynata Therapeutics announces trial in critical COVID-19 patients using...

Cynata Therapeutics (ASX: CYP) COO Kilian Kelly joined Steve Darling from Proactive Vancouver with news the unique stem cell biotech company is beginning a trial in patients suffering from the effects of the coronavirus. Kelly telling Proactive how their technology works and why this...

on 15/5/20

2 min read